Literature DB >> 29055223

Pituitary apoplexy - A single center retrospective study from the neurosurgical perspective and review of the literature.

Agnieszka Grzywotz1, Bernadette Kleist2, Lars C Möller3, Volkmar H Hans4, Sophia Göricke5, Ulrich Sure6, Oliver Müller7, Ilonka Kreitschmann-Andermahr8.   

Abstract

OBJECTIVE: Thunderclap headache and visual disturbances are typical clinical features of pituitary apoplexy (PA). Because of the acute symptomatology, many patients are referred to a neurosurgical department without prior endocrinological assessment. It is the aim of the present study to analyze initial presenting symptoms, outcome and associated endocrine disturbances in a cohort of patients with pituitary apoplexy primarily seen by neurosurgeons. PATIENTS AND METHODS: Retrospective single-center study in a neurosurgical department. Patients' records were reviewed for clinical, neuropathological and endocrinological findings. The diagnosis of PA was based on clinical, imaging and histological findings.
RESULTS: A total of 60 patients were studied. They were referred most often by neurologists (n=16), and family physicians (n=12). Only 2 patients received an endocrinological work-up prior to admission. The most frequently documented presenting symptoms were headache (n=54), visual field defects (n=13), reduction of visual acuity (n=17) and/or diplopia (n=19). An endocrinological history had rarely been taken and hormone blood tests were oftentimes incomplete or not ordered. At 3-month follow-up 18/44 patients had complete anterior hypopituitarism. At 12 months, 21/60 patients were lost to endocrinological follow-up.
CONCLUSIONS: The classic neurological symptoms of PA were well documented in our patient cohort, whereas endocrinological symptoms, especially those indicative of pituitary dysfunction were underreported. Neurologists and neurosurgeons need to be aware of the endocrinological sequelae of pituitary apoplexy in order to avoid potentially lethal complications. Patients should be counselled to adhere to long-term endocrinological and neurosurgical follow-up.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Addisonian crisis; Hypocortisolism; Hyponatremia; Pituitary apoplexy; Thunderclap headache

Mesh:

Year:  2017        PMID: 29055223     DOI: 10.1016/j.clineuro.2017.10.006

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  The surgical management of pituitary apoplexy with occluded internal carotid artery and hidden intracranial aneurysm: illustrative case.

Authors:  Jian-Dong Zhu; Sungel Xie; Ling Xu; Ming-Xiang Xie; Shun-Wu Xiao
Journal:  J Neurosurg Case Lessons       Date:  2021-08-02

2.  Risk factors for the incidence of apoplexy in pituitary adenoma: a single-center study from southwestern China.

Authors:  Yao Li; Yuan Qian; Yisheng Qiao; Xiaoxiang Chen; Jiaotian Xu; Chao Zhang; Wei Wang; Junjun Li; Xingli Deng
Journal:  Chin Neurosurg J       Date:  2020-07-07

Review 3.  Apoplexy in nonfunctioning pituitary adenomas.

Authors:  Luiz Eduardo Wildemberg; Andrea Glezer; Marcello D Bronstein; Mônica R Gadelha
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

4.  The Effect of Timing of Surgery in Pituitary Apoplexy on Continuously Valued Visual Acuity.

Authors:  Patrick D Kelly; Shanik J Fernando; Jordan A Malenke; Rakesh K Chandra; Justin H Turner; Lola B Chambless
Journal:  J Neurol Surg B Skull Base       Date:  2020-01-24

5.  Endoscopic Endonasal Transsphenoidal Approach for the Surgical Treatment of Pituitary Apoplexy and Clinical Outcomes.

Authors:  Zhixiang Sun Md; Xintao Cai Md; Yu Li Md; Dongqi Shao Md; Zhiquan Jiang PhD
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

6.  Conservative treatment cures an elderly pituitary apoplexy patient with oculomotor paralysis and optic nerve compression: a case report and systematic review of the literature.

Authors:  Yanghua Fan; Xinjie Bao; Renzhi Wang
Journal:  Clin Interv Aging       Date:  2018-10-12       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.